Voyager Therapeutics, Inc.

VYGR · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders14.8%

Institutions57.9%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$40.37M	$80.00M	$250.01M	$40.91M	$37.41M	$171.13M	$104.39M	$7.62M	$10.13M	$14.22M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$131.84M	-$83.29M	$122.01M	-$50.84M	-$73.62M	$27.38M	-$51.68M	-$91.09M	-$71.86M	-$41.30M
Operating income as a percentage of revenue.	-326.6%	-104.1%	48.8%	-124.3%	-196.8%	16.0%	-49.5%	-1195.6%	-709.1%	-290.4%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$119.72M	-$65.00M	$132.33M	-$46.41M	-$71.20M	$36.74M	-$43.60M	-$88.29M	-$70.70M	-$40.19M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-2.00	$-1.00	$3.00	$-1.00	$-1.89	$0.99	$-1.21	$-2.75	$2.00	$1.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-2.00	$-1.00	$2.00	$-1.00	$-1.89	$0.98	–	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$65.30M	$71.37M	$68.80M	$98.96M	$117.43M	$104.44M	$86.04M	$46.86M	$31.53M	$36.64M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$252.28M	$393.05M	$351.28M	$159.36M	$193.85M	$261.58M	$354.76M	$177.03M	$184.48M	$189.57M
Everything the company owes — debt, unpaid bills, and other obligations.	$56.20M	$93.29M	$114.96M	$100.34M	$98.80M	$107.26M	$255.25M	$130.58M	$50.43M	$53.64M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$196.08M	$299.76M	$236.32M	$59.02M	$95.06M	$154.32M	$99.51M	$46.45M	$134.05M	$135.92M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$132.47M	-$15.31M	$77.92M	-$12.51M	-$53.52M	-$96.72M	$48.67M	-$15.89M	-$61.35M	-$42.48M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$2.60M	$3.52M	$3.26M	$2.49M	$1.61M	$12.10M	$7.72M	$4.30M	$3.98M	$5.03M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$135.06M	-$18.83M	$74.66M	-$15.00M	-$55.13M	-$108.81M	$40.95M	-$20.19M	-$65.33M	-$47.51M

	You	Peer avg
Revenue Growth	-39.1%	–
ROE	-54.1%	-69.5%

Voyager Therapeutics, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison